Sugi Predict

Sugi Predict / Compounds / SCHEMBL1711599

SCHEMBL1711599

SCHEMBL1711599

CC(C)(C)OC(=O)N1CCN([C]=O)CC1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ HPGD P15428 1/20 0.46
▸ EPHX2 P34913 1/20 0.45
▸ POLB P06746 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ EPHX1 P07099 1/20 0.44
▸ STS P08842 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HTT P42858 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18294 0.85 USP2 (0.69) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL698803 0.85 USP2 (0.69) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL386895 0.83 USP2 (0.53) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL27036913 0.83 USP2 (0.53) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL31218688 0.81 USP2 (0.51) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL485772 0.80 USP2 (0.58) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL15365167 0.80 USP2 (0.58) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL10292758 0.80 USP2 (0.58) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL16612394 0.79 USP2 (0.62) USP2SMN1; SMN2MEN1KMT2AHPGD
SCHEMBL27388627 0.79 USP2 (0.62) USP2SMN1; SMN2MEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019046465-A2 THERAPEUTIC INDOLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-03-07 — — WO claimed
EP-3402791-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS Janssen Pharmaceutica, N.V. (BE) 2018-11-21 — — EP claimed
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2018-06-19 — — US claimed
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-08-17 — — US claimed
WO-2017123542-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-07-20 — — WO claimed
JP-2006516587-A — — 2006-07-06 — — JP claimed
EP-1599204-A2 SELECTIVE MGLU5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT Recordati Ireland Limited (IE) 2005-11-30 — — EP claimed
US-20040215284-A1 Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists RECORDATI S.A. 2004-10-28 — — US claimed
WO-2004067002-A2 SELECTIVE mGlu5 ANTAGONISTS FOR TREATMENT OF NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT RECORDATI IRELAND LIMITED (IE) 2004-08-12 — — WO claimed
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 — — US claimed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 — — US claimed
JP-2002539201-A — — 2002-11-19 — — JP claimed
EP-1161422-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 — — EP claimed
WO-2000055144-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 — — WO claimed
EP-0861249-A1 SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1998-09-02 — — EP claimed
US-5753660-A Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors G. D. SEARLE & CO. (US) 1998-05-19 — — US claimed
WO-1997018205-A1 SUBSTITUTED SULFONYLALKANOYLAMINO HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE & CO. (US) 1997-05-22 — — WO claimed
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers SYNTARGA BV (NL) 2021-07-06 — — US disclosed
EP-0481311-A2 Aminoacid derivatives MERCK PATENT GmbH (DE) 1992-04-22 — — EP disclosed
EP-0474008-A1 Amino acid derivatives MERCK PATENT GmbH (DE) 1992-03-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS AR, SHBG, NR5A1 USP2 2703/4885SMN1; SMN2 4775/4885MEN1 1369/4885
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists AR, SHBG, NR5A1 USP2 2703/4885SMN1; SMN2 4775/4885MEN1 1369/4885
US-11052155-B2 Conjugates of CC-1065 analogs and bifunctional linkers PCNA, DCLRE1A, CDC5L USP2 403/4885SMN1; SMN2 646/4885MEN1 1247/4885
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ USP2 214/4885SMN1; SMN2 4034/4885MEN1 4023/4885
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE USP2 820/4885SMN1; SMN2 3374/4885MEN1 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.